LDHA and acute myeloid leukemia: It will be of interest to explore the therapeutic potential of LDHA inhibitors in future in vivo studies, for example using patient-derived AML xenografts harboring different genetic mutations, to test the efficacy of LDHA inhibitors in eradicating LSCs with high glycolytic signatures, investigate the effects in AMLs carrying metabolically-distinct subclones and study potential escape mechanisms.